Modeling effectiveness of testing strategies to prevent COVID-19 in nursing homes —United 1

- States, 2020 2
- Authors: Isaac See, MD¹, Prabasaj Paul, PhD¹, Rachel B. Slayton, PhD¹, Molly K. Steele, PhD¹, 3
- 4 Matthew J. Stuckey, PhD¹, Lindsey Duca, PhD^{1,2}, Arjun Srinivasan, MD¹, Nimalie Stone, MD¹,
- John A. Jernigan, MD¹, Sujan C. Reddy, MD¹ 5
- 6

7 Affiliations:

- 8 ¹CDC COVID-19 Response Team, Atlanta, GA, United States
- 9 ²Epidemic Intelligence Service, CDC, Atlanta, GA, United States
- 10
- Keywords: nursing homes, testing, COVID-19, infection control, public health 11

12

- 13 Running title: COVID-19 nursing home testing strategies (limit: 40 characters)
- 14
- Post-publication corresponding author and alternate pre-publication corresponding author: 15
- 16 Sujan Reddy, 1600 Clifton Rd HT 16-3, Centers for Disease Control and Prevention, Atlanta, GA
- 30329, (404) 718-6665, sreddy2@cdc.gov 17
- 18 Pre-publication corresponding author: Isaac See, 1600 Clifton Rd HT 16-3, Centers for Disease
- Control and Prevention, Atlanta, GA 30329, (404) 639-0028, isee@cdc.gov 19
- 20
- Article type: major article 21

22

23 Word count: 2999 (limit 3000)

24

- **Summary** (limit: 40 words) Mathematical modeling evaluated the effectiveness of serially 25
- 26 testing asymptomatic persons in a nursing home in response to a SARS-CoV-2 outbreak with or
- without serial testing of asymptomatic staff in the absence of known SARS-CoV-2 infections. 27
- 28
- 29
- 30

31 Abstract:

32

- 33 **Background**: SARS-CoV-2 outbreaks in nursing homes can be large with high case fatality.
- 34 Identifying asymptomatic individuals early through serial testing is recommended to control
- 35 COVID-19 in nursing homes, both in response to an outbreak ("outbreak testing" of residents
- 36 and healthcare personnel) and in facilities without outbreaks ("non-outbreak testing" of
- 37 healthcare personnel). The effectiveness of outbreak testing and isolation with or without non-
- 38 outbreak testing was evaluated.
- 39 **Methods**: Using published SARS-CoV-2 transmission parameters, the fraction of SARS-CoV-2
- 40 transmissions prevented through serial testing (weekly, every three days, or daily) and isolation
- of asymptomatic persons compared to symptom-based testing and isolation was evaluated
- 42 through mathematical modeling using a Reed-Frost model to estimate the percentage of cases
- 43 prevented (i.e., "effectiveness") through either outbreak testing alone or outbreak plus non-
- 44 outbreak testing. The potential effect of simultaneous decreases (by 10%) in the effectiveness
- 45 of isolating infected individuals when instituting testing strategies was also evaluated.
- 46 **Results:** Modeling suggests that outbreak testing could prevent 54% (weekly testing with 48-
- 47 hour test turnaround) to 92% (daily testing with immediate results and 50% relative sensitivity)
- 48 of SARS-CoV-2 infections. Adding non-outbreak testing could prevent up to an additional 8% of
- 49 SARS-CoV-2 infections (depending on test frequency and turnaround time). However, added
- 50 benefits of non-outbreak testing were mostly negated if accompanied by decreases in infection
- 51 control practice.
- 52 **Conclusions**: When combined with high-quality infection control practices, outbreak testing
- could be an effective approach to preventing COVID-19 in nursing homes, particularly if
- 54 optimized through increased test frequency and use of tests with rapid turnaround.

55

56 Word count: 248 (limit 250)

57

58

59 Introduction

- 60 Coronavirus disease 2019 (COVID-19) has posed a significant public health challenge for nursing
- 61 homes in the United States [1,2]. To prevent introduction and transmission of SARS-CoV-2,
- 62 nursing homes have been recommended to implement precautions including monitoring
- 63 symptoms of residents and healthcare personnel (HCP), testing symptomatic persons promptly,
- 64 and instituting infection control practices including, but not limited to, isolating individuals with
- 65 COVID-19 [3]. In addition, because asymptomatic and pre-symptomatic infected individuals can
- 66 transmit SARS-CoV-2, identifying such infected individuals early through serial testing is also
- 67 recommended to control COVID-19 in nursing homes both as part of an outbreak response as
- 68 well as in facilities not experiencing outbreaks [4–6]. When responding to an outbreak, CDC
- 69 currently recommends testing all residents and HCP every 3–7 days until no new cases are
- identified. In addition, in facilities not experiencing an outbreak, serial testing of all HCP is
- currently recommended, at intervals dependent on the level of county transmission [6].

72 Infection prevention and control strategies in nursing homes might be hampered by

rages of testing supplies [7] and the time-consuming effort needed to implement

- 74 widespread testing strategies. The impact of various testing strategies for asymptomatic
- residents and HCP has not been well characterized; understanding the relative benefit of
- testing strategies may help prioritize resources. The objective of this manuscript is to provide
- estimates of the effectiveness (i.e., percentage of COVID-19 cases prevented) of either
- outbreak testing or combining outbreak and non-outbreak testing for preventing COVID-19 in
- nursing homes under different scenarios of test frequency and performance. We also estimate
- 80 the "efficiency" (number of tests needed to prevent a case) of both outbreak and non-outbreak
- 81 testing strategies.

82

83 Methods

84 Definitions

"Outbreak testing" was defined as serial testing (e.g., daily, every three days, weekly) of all 85 86 residents and HCP immediately following recognition of an initial COVID-19 case. "Nonoutbreak testing" was defined as serial testing of HCP in the absence of a known COVID-19 87 case. Mathematical modeling was used to evaluate two paradigms for using testing to help 88 control COVID-19 in nursing homes: (1) outbreak testing that begins immediately following 89 recognition of an initial case, and (2) non-outbreak testing in facilities when outbreaks are not 90 occurring combined with outbreak testing once cases are identified. Testing frequency, 91 92 turnaround time, and sensitivity were varied to broadly reflect testing capabilities as of November 2020. The primary quantities of interest were the "effectiveness" of a testing 93 strategy, defined as the percent of cases prevented; and the "efficiency" of a testing strategy, 94 defined as the number of cases prevented divided by the number of tests used. 95

Evaluating these strategies for a "typical" nursing home required estimating three 96 quantities through modeling: (1) the expected number of SARS-CoV-2 infections occurring in an 97 outbreak without testing of asymptomatic persons, i.e., infection control is guided only by 98 testing and isolating symptomatic residents and HCP. This quantity is considered the "baseline" 99 100 outbreak size because, conceptually, our evaluation is for paradigms of testing asymptomatic 101 persons. (2) the expected number of SARS-CoV-2 infections occurring per outbreak when outbreak testing is conducted. The difference between (2) and (1) is the number of cases 102 prevented by outbreak testing.(3) the expected percentage of SARS-CoV-2 outbreaks prevented 103 104 by non-outbreak testing.

- 105 Parameters used for the model and estimates were set as follows: during the early months of the pandemic the mean number of residents from Centers for Medicare & Medicaid 106 Services (CMS)-certified nursing homes was 86 [8]. The HCP per resident ratio was set at 1.5:1, 107 vielding 129 HCP at the facility based on the following rationale: analysis of the payroll-based 108 journal data from the Centers for Medicare and Medicaid Services (PBJ) suggest that on 109 average 1.2 full-time equivalent HCP per resident are employed by each nursing home [9]. 110 However, this likely represents a minimum estimate because some HCP work part-time. In 111 some areas where facility-wide testing of and residents has been conducted, the HCP per 112 113 resident ratio has been as high as 2:1 (CDC, unpublished data). The ratio of 1.5 HCP per resident was chosen as closer to the midpoint of these estimates. Although these HCP 114 115 estimates HCP may include some who do not have direct resident contact, such HCP could still contribute to SARS-CoV-2 transmission (e.g., HCP-to-HCP). Estimates of infectivity from 116 asymptomatic or pre-symptomatic persons [10] varied over the course of illness and were used 117 118 to calculate the expected reduction of transmission occurring from detecting these people through testing and isolating them (supplemental methods). All scenarios model introductions 119 120 of SARS-CoV-2 into the facility through HCP only, e.g., no visitors are permitted. A summary of model inputs can be found in Table 1. 121
- 122

123 Calculation of estimates

124 To estimate the expected size of an outbreak at baseline, a Reed-Frost model, in which the susceptible individuals in a population of size N have probability $p = \frac{R}{N-1}$ of becoming 125 infected at each stage of transmission [11], was used to model the transmission of SARS-CoV-2 126 during a nursing home outbreak. The Reed-Frost model was chosen because it is well-suited for 127 128 capturing stochasticity of transmissions in finite-sized congregate settings. The total population 129 size is the number of residents plus the number of HCP. We estimated the reproductive number R₀ for outbreaks under the following conditions: (1) the only testing occurring was of 130 131 symptomatic persons, (2) isolation of symptomatic persons occurred, and (3) recommendations 132 for other established infection control practices (e.g., isolating patients, universal facemasks and cloth face coverings) were in place. This estimate of R₀, based on data for nursing home 133

outbreaks from Colorado during the early period of the pandemic (supplemental methods), is referred to as the "unmitigated" R_0 and used to generate the baseline outbreak size.

To determine outbreak size when using outbreak testing, modeling based on viral
 dynamics of SARS-CoV-2 was used to estimate the reduction in transmission µ expected from
 the testing strategy (supplemental methods). The mitigated reproductive number R₀' was
 calculated by multiplying the unmitigated R₀ by the reduction in transmission µ expected from
 the testing strategy and used to estimate outbreak size using outbreak testing.

For non-outbreak testing, the proportion of outbreaks prevented was set to equal μ.
This corresponds to an assumption that an outbreak (at baseline) will typically be introduced by
a single person so that the proportion of transmissions prevented equals the proportion of
outbreaks averted and represents a best-case scenario for non-outbreak testing regardless of
the level of community transmission. As outlined in the supplemental methods, this was
combined with estimates for outbreak testing to determine the effectiveness and efficiency of
using both outbreak and non-outbreak testing.

The "baseline" test sensitivity was modeled to vary during the course of illness with test 148 149 sensitivity proportional to infectiousness early in the course of illness (supplemental methods). Peak sensitivity was set at 95% reflecting best understanding of reported reverse-transcriptase 150 polymerase chain reaction (RT-PCR) test characteristics [12]. To mirror realistic and 151 recommended tests available, outbreak and non-outbreak testing strategies were primarily 152 evaluated with weekly and every-three-days testing intervals with either a 24-hour or 48-hour 153 154 turnaround time and sensitivity corresponding to RT-PCR; or an estimated sensitivity of 85% 155 (compared to RT-PCR tests), with immediate turnaround time, i.e., point-of-care test (supplemental methods). The lower sensitivity of 85% was chosen to match the lower end of 156 157 the range of sensitivity reported for currently available point-of-care tests [13]. We also 158 evaluated a hypothetical outbreak and non-outbreak testing strategy in which a point-of-care 159 test with 50% sensitivity is used for daily testing. These testing scenarios with lower sensitivity 160 were evaluated because some investigators have advocated for the development and adoption of rapid tests with lower sensitivity [14]. We also evaluated weekly and every-three-days 161 162 testing with a lower sensitivity (50%) point-of-care platform because of reports that existing 163 point-of-care tests may have lower sensitivity for detecting asymptomatic individuals [15].

164

165 Sensitivity analyses and other variations

The above analyses evaluated the impact of adding non-outbreak testing to outbreak testing with a 10% probability of SARS-CoV-2 introduction to a facility during the week that testing occurs, which corresponded to the overall national picture during July-September 2020 (supplemental methods). As a sensitivity analysis, this probability was increased to evaluate the potential impact of non-outbreak testing in areas with higher levels of community transmission.

We considered that implementing a more comprehensive testing strategy require additional resources (e.g., staff time, protective equipment). We postulated that these increases might have a deleterious effect on a facility's ability to control transmission through adherence to infection control protocols. To estimate this effect, we calculated the impact of a

relatively small (i.e., 10%) decrease (from a default of 100%) in the effectiveness of preventing
 transmission by isolating infected persons when adding non-outbreak testing to outbreak

177 testing.

Additional sensitivity analyses used adaptations of three alternate infectivity profiles from the literature to calculate the above quantities (supplemental methods; supplemental table S1).

181

182 Administrative information

Modeling calculations were conducted with the statistical software R (version 4.0.2, the R Foundation for Statistical Computing). Additional details about modeling can be found in a supplemental section. Code for the models can be found on the CDC Epidemic Prediction Initiative GitHub site (https://github.com/cdcepi/Nursing-home-SARS-CoV-2-testing-model/).

This activity was reviewed by CDC and was conducted consistent with applicable federal law and CDC policy (see e.g., 45 C.F.R. part 46, 21 C.F.R. part 56; 42 U.S.C. §241(d); 5 U.S.C §552a; 44 U.S.C. §351 et seq.).

190

191 Results:

192 Effectiveness and efficiency of outbreak and non-outbreak testing

At all currently recommended testing intervals with acceptable turnaround times (i.e., 48 hours 193 or less), outbreak testing alone is estimated to prevent 54% (weekly testing with 48-hour 194 turnaround time) to 90% of cases (point-of-care testing every three days) associated with a 195 COVID-19 outbreak (Table 2). Adding weekly or every-three-days non-outbreak testing to 196 197 outbreak testing prevented up to 8% of additional cases. Combining every-three-days outbreak and non-outbreak testing with a point-of-care test prevented 95% of cases. In addition, at a 198 given testing frequency and turnaround time, increasing either the frequency of the testing or 199 decreasing the turnaround time for outbreak testing was estimated to prevent more infections 200 201 than adding non-outbreak testing with the same frequency and turnaround time. In an exploratory analysis, use of a daily POC test with 50% sensitivity was estimated to prevent 92% 202 of cases using outbreak testing alone and 97% of cases using both outbreak and non-outbreak 203 204 testing.

205 Combining outbreak and non-outbreak testing in the setting of a 10% decrease in the 206 effectiveness of isolating infected persons prevented fewer cases than outbreak testing alone

207 with complete effectiveness of isolation for all testing frequencies, turnaround, and test

208 sensitivity scenarios evaluated except when testing every three days with 24-hour turnaround

time or POC testing with 85% sensitivity. In these scenarios, adding non-outbreak testing but

210 decreasing effectiveness of isolating infected persons was estimated to prevent an additional 2-

211 3% of cases compared to outbreak testing alone with complete effectiveness of isolation.

The number of tests needed to prevent a case through outbreak testing alone (range: 41-145 tests/case prevented) was lower than through combining outbreak and non-outbreak

- 214 testing (range: 60-238).
- 215

216 Varying likelihood of SARS-CoV-2 introduction from the community

When conducting outbreak and non-outbreak testing every three days with a point-ofcare test with 85% sensitivity, as the likelihood of SARS-CoV-2 introductions per week increased, the percent of cases prevented was estimated to remain unchanged at 95% (Figure). However, as the likelihood of SARS-CoV-2 introductions increased, the number of tests needed to prevent a case was estimated to decrease from 90 tests/case prevented at a 10% likelihood of introductions to 9 tests/case prevented at a 100% likelihood of introductions when combining outbreak and non-outbreak testing (Figure).

224

225 Sensitivity analyses

As a sensitivity analysis when using alternative infectivity profiles (Table S1), the 226 magnitude of benefit of outbreak testing varied (Tables S2-S4). For example, testing weekly 227 with 48-hour turnaround prevented 31–74% of infections depending on the infectivity profile. 228 However, in all of these sensitivity analyses adding non-outbreak testing added a relatively 229 small percentage benefit to outbreak testing alone, not exceeding 8% for any test 230 turnaround/frequency/sensitivity regardless of infectivity profile. In addition, for all but one 231 infectivity profile (Table S4), for the majority of testing scenarios modeled outbreak testing 232 alone was superior to combining outbreak and non-outbreak testing if combined testing was 233 234 associated with decreases in effectiveness of isolating patients.

235

236 Discussion

Preventing COVID-19 in nursing homes is a high priority for the pandemic response [16]. In our
analysis, serially testing asymptomatic residents and HCP in response to an outbreak to guide
infection control response prevented the majority of SARS-CoV-2 infections in a hypothetical
nursing home with 86 residents and 129 staff. In addition, optimizing and prioritizing outbreak
testing to facilitate increased test frequency with rapid turnaround times while maintaining

high-quality infection control practice is estimated to be an efficient strategy while also nearlymaximizing number of infections prevented.

244 Ensuring robust symptom identification with prompt testing in response to a potential 245 new SARS-CoV-2 infection, and subsequently eliminating transmission from persons with COVID-19 through isolation, is essential for responses using outbreak testing to be effective. 246 Nursing homes with outbreaks frequently face staff shortages [17], which may limit capacity to 247 perform necessary patient care activities, infection prevention activities, or increased testing. If 248 redirecting resources from recommended infection control practices to testing leads to small 249 250 reductions in the effectiveness of infection control practices, then the combination of outbreak 251 and non-outbreak testing could be less effective than just performing outbreak testing with high-quality infection control. These considerations are all the more important because real-252 life conditions in a nursing home might not correspond to ideal implementation. For example, 253 254 isolation of patients can be difficult if there are no empty rooms; and isolated patients still need care and therefore could still pose some risk of transmission to staff. 255

These findings also support current recommendations from CDC and CMS [6.18] to 256 prioritize testing of symptomatic residents and HCP first, followed by testing residents and staff 257 258 in response to outbreaks, and finally non-outbreak testing of asymptomatic HCP. The addition 259 of non-outbreak testing may provide a modest benefit, although it requires more testing resources to prevent each COVID-19 case. The testing resources required (per case prevented) 260 did decrease as the likelihood of SARS-CoV-2 introductions (i.e., level of community 261 262 transmission) increased. The impact is still only modest even when SARS-CoV-2 introductions 263 are more frequent than observed in the United States in July-September 2020. The reason that non-outbreak testing only has a modest benefit is that the benefit of non-outbreak testing 264 relies on the ability to identify infected persons at key times in the course of their illness: the 265 pre-symptomatic infectious period and, for asymptomatic individuals, the period of peak 266 infectiousness. Both of these time periods are narrow (e.g., pre-symptomatic period of 2-3 267 268 days) and easily missed without very frequent (e.g., every-three-days or more often) testing [10,14]. Furthermore, implementing high-quality outbreak response leads to smaller outbreaks, 269 270 which then reduces the added benefit of non-outbreak testing because the outbreaks 271 prevented through non-outbreak testing are smaller in size.

The results described in this paper also support current recommendations that performing outbreak testing every three days is the preferred frequency when initiating an outbreak response, if this does not detract from other important activities such as infection control procedures [18]. In general, testing strategies with better turnaround time and higher frequency were estimated to be more effective if other conditions (e.g., infection control practices) remained constant.

The federal government is providing nursing homes with point-of-care antigen testing platforms [19]. The analysis conducted in this manuscript suggests that the advantage of faster turnaround time from such platforms may outweigh the disadvantage of potential lower

sensitivity. Practical considerations may still limit how frequently these tests can be performed
through serial testing strategies. An exploratory analysis suggested that a hypothetical strategy
using daily point-of-care testing with lower (e.g., 50%) sensitivity could be as effective as, or
even more effective than, relying on more sensitive tests used less frequently. Daily testing is
likely not currently feasible in all nursing homes and would need widespread availability of
inexpensive, simple testing options that could be run on easy-to-collect specimen types. In
addition, making a test with 50% sensitivity available (that might facilitate daily testing) would

require changes to the current regulatory framework [20–24].

289 These findings are subject to at least the following limitations. First, the analysis used 290 mathematical modeling rather than directly studying an implementation. However, the model parameters have been reviewed as suitable to use for pandemic planning scenarios and are 291 based on observational data about SARS-CoV-2 transmission [10]. The patterns seen and 292 comparisons made from results, therefore, are likely reasonable even if the absolute estimates 293 294 themselves may lack precision. Second, outbreaks in facilities have been assumed to be independent. Since some HCP work in more than one facility [4], the potential effectiveness of 295 both testing strategies has been underestimated on a population level. Third, other unintended 296 297 consequences of asymptomatic testing were not evaluated, such as identifying false positives 298 during non-outbreak testing with population prevalence of COVID-19. Even if using a test with 99.4% specificity, most facilities without COVID-19 might expect at least one false positive 299 result after testing all its staff. Fourth, there is uncertainty around the parameters used for the 300 model. For example, the actual infectivity profile of SARS-CoV-2 infection is not known with 301 certainty, although our main conclusions appear to be robust when evaluating several 302 303 published infectivity profiles. As another example, the proportion of patients with asymptomatic infections has varied in the reported literature [25,26]. Fifth, we have not 304 305 accounted for how the accumulation of persons with immunity over the course of time might affect strategies. Finally, if infection control practices, in general, are not optimal, then the 306 307 benefits of testing strategies will be less than we have estimated. For example, we assume that outbreak testing occurs immediately after identification of a recognized case, while in practice 308 delays could occur. 309

In summary, testing asymptomatic persons in response to an outbreak is an effective and efficient strategy to supplement optimized infection control practices to limit SARS-CoV-2 transmissions in nursing homes. The benefit of outbreak testing strategies may increase with more frequent outbreak testing with rapid turnaround times, but most importantly require careful effort to ensure that infection control measures are effectively implemented.

315

316 Acknowledgements

- 317 The authors would like to thank Christopher Czaja, MD, DrPH (Colorado Department of Public
- 318 Health and Environment) for discussions about nursing home outbreak response in Colorado
- 319 early in the COVID-19 pandemic.
- 320

321 Conflicts of interest

- 322 None
- 323
- 324 Funding
- 325 This work was funded by the Centers for Disease Control and Prevention.
- 326

327 Disclaimer

- 328 The findings and conclusions in this report are those of the authors and do not necessarily
- 329 represent the views and the official position of the Centers for Disease Control and Prevention.
- 330

331 References

332 1. Centers for Medicare and Medicaid Services. COVID-19 Nursing Home Data. https://data.cms.gov/stories/s/COVID-19-Nursing-Home-Data/bkwz-xpvg/. Last 333 334 accessed September 25, 2020. 2. Arons MM, Hatfield KM, Reddy SC, Kimball A, James A, Jacobs JR, et al. Presymptomatic 335 336 SARS-CoV-2 infections and transmission in a skilled nursing facility. New Engl J Med. 2020 Apr 24;382(22):2081-2090. 337 3. Centers for Disease Control and Prevention. Preparing for COVID-19 in Nursing Homes. 338 Available at: https://www.cdc.gov/coronavirus/2019-ncov/hcp/long-term-care.html. 339 Accessed 19 November 2020. 340 341 4. McMichael TM, Clark S, Pogosjans S, Kay M, Lewis J, Baer A, et al. COVID-19 in a Long-342 Term Care Facility — King County, Washington, February 27–March 9, 2020. MMWR Morb Mort Weekly Rep. 2020 March 27;69(12):339-342. 343 5. Centers for Disease Control and Prevention. Testing Guidelines for Nursing Homes. 344 345 Available at: https://www.cdc.gov/coronavirus/2019-ncov/hcp/nursing-homestesting.html. Accessed 19 November 2020. 346 6. Centers for Medicare & Medicaid services Center for Clinical Standards and 347 Quality/Survey & Certification Group. QSO-20-38-NH. Available at: 348 https://www.cms.gov/files/document/qso-20-38-nh.pdf. Accessed 19 November 2020. 349

350	7.	American Society for Microbiology. Supply Shortages Impacting COVID-19 and Non-
351		COVID Testing. Available at: <u>https://asm.org/Articles/2020/September/Clinical-</u>
352		Microbiology-Supply-Shortage-Collecti-1 Accessed November 4, 2020
353	8.	Centers for Medicare and Medicaid Services. Nursing Home Compare datasets.
354		Available at: <u>https://data.medicare.gov/data/nursing-home-compare</u> . Last accessed
355		October 5, 2020.
356	9.	Centers for Medicare and Medicaid Services. PBJ Public Use Files Data Documentation.
357		Available at: https://data.cms.gov/Special-Programs-Initiatives-Long-Term-Care-
358		Facili/PBJ-Public-Use-Files-Data-Documentation/ygny-gzks. Last accessed September
359		23, 2020
360	10	Centers for Disease Control and Prevention. COVID-19 Pandemic Planning Scenarios.
361		Available at: <u>https://www.cdc.gov/coronavirus/2019-ncov/hcp/planning-scenarios.html.</u>
362		Accessed 19 November 2020.
363	11.	Halloran E, Longini IM Jr, Struchiner CJ. Design and Analysis of Vaccine Studies. Chapter
364		4: Binomial and Stochastic Transmission Models. Springer New York, New York, New
365		York: 2009. Available at:
366		http://courses.washington.edu/b578a/readings/bookchap4.pdf. Accessed 2020
367		November 20.
368	12	Kucirka L, Lauer S, Laeyendecker O, Boon D, Lessler J. Variation in False Negative Rate of
369		RT-PCR Based SARS-CoV-2 Tests by Time Since Exposure. medRXiv
370		2020.04.07.20051474 [Preprint]. April 10, 2020 [cited 2020 Nov 19]. Available from:
371		https://www.medrxiv.org/content/10.1101/2020.04.07.20051474v1
372	13	Centers for Disease Control and Prevention. Interim Guidance for Rapid Antigen Testing
373		for SARS-CoV-2. Available at: <u>https://www.cdc.gov/coronavirus/2019-</u>
374		ncov/lab/resources/antigen-tests-guidelines.html. Accessed 2020 November 19.
375	14	Larremore DB, Wilder B, Lester E, Shehata S, Burke JM, Hay JA, et al. Test sensitivity is
376		secondary to frequency and turnaround time for COVID-19 surveillance. medRxiv
377		2020.06.22.20136309 [Preprint]. September 8, 2020 [cited 2020 Nov 19]. Available
378		from: <u>https://www.medrxiv.org/content/10.1101/2020.06.22.20136309v3</u>
379	15	A Rapid Virus Test Falters in People Without Symptoms, Study Finds. The New York
380		Times. November 2, 2020. Available at:
381		https://www.nytimes.com/2020/11/02/health/coronavirus-testing-quidel-sofia.html.
382		Accessed 19 November 2020.
383	16	U.S. White House. President Donald J. Trump Is Taking Strong Action to Further Protect
384		Nursing Homes from the Coronavirus. Available at:
385		https://www.whitehouse.gov/briefings-statements/president-donald-j-trump-is-taking-
386		decisive-action-to-protect-vulnerable-citizens-in-americas-nursing-homes/. Accessed
387		2020 November 19.
388	17	. Taylor J, Carter RJ, Lehnertz N, Kazazian L, Sullivan M, Wang X, Garfin J, et al. Serial
389		Testing for SARS-CoV-2 and Virus Whole Genome Sequencing Inform Infection Risk at

390	Two Skilled Nursing Facilities with COVID-19 Outbreaks — Minnesota, April–June 2020.
391	MMWR Morb Mortal Wkly Rep 2020 Sep 18;69(37):1288–1295.
392	18. Centers for Disease Control and Prevention. Clinical Questions about COVID-19:
393	Questions and Answers. Available at: <u>https://www.cdc.gov/coronavirus/2019-</u>
394	ncov/hcp/faq.html#Testing-in-Nursing-Homes. Accessed 5 October 2020.
395	19. U.S. Department of Health and Human Services. Trump Administration Announces
396	Initiative for More and Faster COVID-19 Testing in Nursing Homes. Available at:
397	https://www.hhs.gov/about/news/2020/07/14/trump-administration-announces-
398	initiative-more-faster-covid-19-testing-nursing-homes.html. Accessed 2020 November
399	20.
400	20. U.S. Food and Drug Administration (FDA). In Vitro Diagnostics EUAs. Available at:
401	https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-
402	use-authorizations-medical-devices/vitro-diagnostics-euas. Accessed 2020 November
403	27.
404	21. U.S. Food and Drug Administration (FDA). Molecular Diagnostic Template for
405	Commercial Manufacturers. Available at:
406	https://www.fda.gov/media/135900/download. Accessed 2020 November 27.
407	22. U.S. Food and Drug Administration (FDA). Molecular Diagnostic Template for
408	Laboratories. Available at: <u>https://www.fda.gov/media/135658/download</u> . Accessed
409	2020 November 27.
410	23. U.S. Food and Drug Administration (FDA). Antigen Template for Test Developers.
411	Available at: https://www.fda.gov/media/137907/download . Accessed 2020 November
412	27.
413	24. U.S. Food and Drug Administration (FDA). Template for Manufacturers of Molecular and
414	Antigen Diagnostic COVID-19 Tests for Non-Laboratory Use. Available at:
415	https://www.fda.gov/media/140615/download. Accessed 2020 November 27.
416	25. Yanes-Lane M, Winters N, Fregonese F et al. Proportion of asymptomatic infection
417	among COVID-19 positive persons and their transmission potential: A systematic review
418	and meta-analysis. PLoS One. November 3, 2020. 15(11):e0241536.
419	https://doi.org/10.1371/journal.pone.0241536
420	26. Johansson MA, Quandelacy TM, Kada S, et al. SARS-CoV-2 transmission from people
421	without COVID-19 symptoms. JAMA Network Open. 2021;4(1):e2035057.
422	
423	

424 **Table 1:** Model inputs

Variable	Value	Source/reference
Number of residents	86	Estimated as occupied beds
		from Nursing home compare
		[8]
Number of healthcare personnel	129	1.5 times the number of
		residents
Total population size	215	Number of
		residents+healthcare personnel
R ₀	1.366689	Mean R ₀ estimated from
		outbreak sizes among Colorado
		nursing homes (Supplemental
		methods)
Proportion of transmission from	0.5	CDC Pandemic Planning
symptomatic infections occurring		Scenarios [10]
during presymptomatic phase		
Proportion of infections that are	0.4	CDC Pandemic Planning
asymptomatic		Scenarios [10]
Infectivity of asymptomatic versus	0.75	CDC Pandemic Planning
symptomatic infections		Scenarios [10]

425

Table 2:

Percent SARS-CoV-2 infections prevented and number of tests needed per case prevented when serially testing asymptomatic nursing home residents and staff in response to outbreaks ("outbreak testing"), combining this testing strategy with serial testing of asymptomatic staff in the absence of known cases ("outbreak+non-outbreak testing"), and conducting both outbreak and non-outbreak testing with a concomitant 10% decrease in the effectiveness of halting SARS-CoV-2 transmission through isolating identified cases. Cases occurring using these strategies are compared to the number occurring with use of only symptom-based testing and isolation^a.

			Outbreak	c testing ^b	Outbreak + non-outbreak testing ^{b,c}		Outbreak + non-outbreak testing ^{b,c} , 10% decrease in effectiveness of isolation	
Sensitivity ^d	Turnaround time	Testing frequency	% cases prevented ^e	Tests/case prevented ^e	% cases prevented ^e	Tests/case prevented ^e	% cases prevented ^e	Tests/case prevented ^e
Baseline	48 hours	Weekly	54.1%	67	61.9%	90	45.8%	130
Baseline	24 hours	Weekly	67.8%	47	75.3%	67	63.0%	86
Baseline	48 hours	Every 3 days	79.3%	80	85.9%	121	78.2%	141
Baseline	24 hours	Every 3 days	87.3%	61	92.8%	98	89.4%	106
85%	POC	Weekly	72.9%	41	80.1%	60	69.7%	74
85%	POC	Every 3 days	89.7%	55	94.8%	90	92.7%	95
50% ^f	POC	Weekly	50.9%	73	58.6%	97	41.9%	145
50% ^f	POC	Every 3 days	79.7%	79	86.2%	119	78.8%	140
50% ^f	POC	Daily	92.4%	145	97.1%	238	96.2%	246

POC: point-of-care (i.e., results available immediately)

^a In this situation a mean of 50 cases/outbreak occur.

^b Outbreak testing: serial testing of asymptomatic persons in response to an outbreak

^c Non-outbreak testing: serial testing of asymptomatic healthcare personnel in the absence of known cases

^d Sensitivities of 85% and 50% are relative to the sensitivity of the baseline test, which is modeled to vary during the course of infectiousness and to replicate sensitivity of existing reverse transcriptase polymerase chain reaction (RT-PCR) tests for SARS-CoV-2.

^e The fraction of cases prevented compared to what is expected to occur when performing neither outbreak testing nor nonoutbreak testing but still maintaining effectiveness of isolating patients.

^fNo point-of-care test with this sensitivity is currently available for use in the United States; this testing platform represents a hypothetical situation in that respect or may be a reflection of tests that may have low sensitivity for detecting asymptomatic persons with low viral load.

Figure: Evaluation of how the performance of testing strategies for nursing homes changes as the likelihood of a new SARS-CoV-2 introduction during the week of testing varies. The solid line depicts the percentage of cases prevented when combining outbreak and non-outbreak testing. The dotted line shows tests per case prevented when combining outbreak and non-outbreak testing. Both lines show results for outbreak and non-outbreak testing conducted every 3 days with immediate turnaround (i.e., point-of-care test) and 85% test sensitivity (compared to a reverse-transcriptase polymerase chain reaction [RT-PCR] test).

